ATE227297T1 - 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel - Google Patents

2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel

Info

Publication number
ATE227297T1
ATE227297T1 AT94917922T AT94917922T ATE227297T1 AT E227297 T1 ATE227297 T1 AT E227297T1 AT 94917922 T AT94917922 T AT 94917922T AT 94917922 T AT94917922 T AT 94917922T AT E227297 T1 ATE227297 T1 AT E227297T1
Authority
AT
Austria
Prior art keywords
complexes
derivatives
contrast agents
acid
polyazamacrocyclophosphonic
Prior art date
Application number
AT94917922T
Other languages
English (en)
Inventor
Garry E Kiefer
Won D Kim
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ATE227297T1 publication Critical patent/ATE227297T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/281Means for the use of in vitro contrast agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT94917922T 1993-05-06 1994-05-05 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel ATE227297T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/057,588 US5462725A (en) 1993-05-06 1993-05-06 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
PCT/US1994/005009 WO1994026275A1 (en) 1993-05-06 1994-05-05 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents

Publications (1)

Publication Number Publication Date
ATE227297T1 true ATE227297T1 (de) 2002-11-15

Family

ID=22011534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917922T ATE227297T1 (de) 1993-05-06 1994-05-05 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel

Country Status (17)

Country Link
US (1) US5462725A (de)
EP (1) EP0711300B1 (de)
JP (1) JPH08510245A (de)
CN (1) CN1125905A (de)
AT (1) ATE227297T1 (de)
AU (1) AU678583B2 (de)
BG (1) BG100192A (de)
CA (1) CA2162174A1 (de)
CZ (1) CZ289595A3 (de)
DE (1) DE69431660T2 (de)
FI (1) FI955319A7 (de)
HU (1) HUT74565A (de)
LV (1) LV11430B (de)
NO (1) NO301829B1 (de)
PL (1) PL311643A1 (de)
SG (1) SG46458A1 (de)
WO (1) WO1994026275A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409689A (en) * 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
DE19523891C1 (de) * 1995-06-30 1996-11-21 Hoechst Ag Chirale Mangan-triazanonankomplexe und Verfahren zu ihrer Herstellung
CA2251924C (en) * 1996-04-19 2006-05-30 The Dow Chemical Company Fluorescent chelates as visual tissue specific imaging agents
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US6685914B1 (en) 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
EP1362861B1 (de) * 1999-09-13 2005-12-14 Bristol-Myers Squibb Pharma Company Makrocyclische Chelatbildner für Metallopharmazeutika
DE60006587T2 (de) * 1999-09-13 2004-09-16 Bristol-Myers Squibb Pharma Co. Makrozyclische liganden für metallpharmazeutika
EP1429783A4 (de) * 2001-09-04 2006-08-09 Univ Texas Tech Vielseitig einsetzbare chelate für die multimodale bildeinstellung
DE60207288T2 (de) * 2001-10-22 2006-05-18 Dow Global Technologies, Inc., Midland Gewebespezifische fluoreszierende chelate
WO2003098232A2 (en) * 2002-05-17 2003-11-27 Case Western Reserve University Chemical shift markers for improved wireless fiducial marker tracking
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
EP1637524A1 (de) * 2004-09-20 2006-03-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 10-substituierte 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecanederivate zur Verwendung als Kontrastmittel
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006039505A2 (en) * 2004-09-30 2006-04-13 Molecular Devices Corporation Luminescent lanthanide complexes
EP2032606B1 (de) 2006-05-30 2013-11-27 Genentech, Inc. Antikörper und immunkonjugate sowie ihre verwendungen
BRPI0717638A2 (pt) 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
EP2176295B1 (de) 2007-07-16 2014-11-19 Genentech, Inc. Humanisierte anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-cd79b 항체 및 면역접합체 및 사용 방법
US8499251B2 (en) 2009-01-07 2013-07-30 Microsoft Corporation Virtual page turn
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX2011012665A (es) 2009-06-04 2012-03-07 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
NZ701208A (en) 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2870180B1 (de) 2012-07-04 2024-08-28 F. Hoffmann-La Roche AG Anti-biotin-antikörper und verwendungsverfahren
DK2869837T3 (en) 2012-07-04 2016-09-26 Hoffmann La Roche Anti-theophylline antibodies and methods of use
RU2684595C2 (ru) 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело
CN105899540B (zh) 2014-01-03 2020-02-07 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
EP3089758B1 (de) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Kovalent verknüpfte helikar-/anti-helikar-antikörperkonjugate und verwendungen davon
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CA2966287A1 (en) 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Novel methods for enzyme mediated polypeptide conjugation using sortase
WO2017050866A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Novel soluble sortase a
CN108026560A (zh) 2015-09-25 2018-05-11 豪夫迈·罗氏有限公司 在低共熔溶剂中使用分选酶的转酰胺反应
BR112018003594A2 (pt) 2015-09-25 2018-09-25 Hoffmann La Roche cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
CN108138204B (zh) 2015-09-25 2021-12-31 豪夫迈·罗氏有限公司 使用分选酶a生产硫酯的方法
EP3436578B1 (de) 2016-03-30 2022-01-19 F. Hoffmann-La Roche AG Verbesserte sortase
WO2018191389A1 (en) 2017-04-12 2018-10-18 Roche Sequencing Solutions, Inc. A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction
JP7267253B2 (ja) 2017-07-13 2023-05-01 エフ. ホフマン-ラ ロシュ アーゲー Pivkaに対する新規結合剤およびアッセイ
EP3697813A1 (de) 2017-10-20 2020-08-26 H. Hoffnabb-La Roche Ag Kopierschutz für antikörper
KR102769570B1 (ko) 2017-11-30 2025-02-19 제넨테크, 인크. 항-pd-l1 항체 및 pd-l1 탐지를 위하여 동일한 항체를 이용하는 방법
EP3492460A1 (de) * 2017-12-01 2019-06-05 Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. Verbindungen zur trennung von seltenerdelementen, trennverfahren und verwendung davon
BR112020017941A2 (pt) 2018-03-14 2021-02-17 F. Hoffmann-La Roche Ag anticorpos, moléculas de ácido nucleico, vetor, composição e método de determinação da troponina t cardíaca humana
KR20200131838A (ko) 2018-03-14 2020-11-24 에프. 호프만-라 로슈 아게 항체의 친화성 성숙화를 위한 방법
EP3781600A1 (de) 2018-04-18 2021-02-24 F. Hoffmann-La Roche AG Neuartige anti-thymidinkinase-antikörper
JP7577647B2 (ja) 2018-08-31 2024-11-05 エフ. ホフマン-ラ ロシュ アーゲー Dlbclについての予後指標におけるチミジンキナーゼ(tk-1)
KR20210087938A (ko) 2018-09-28 2021-07-13 이미지냅 인코포레이티드 Cd8 이미징 구조체 및 이의 사용 방법
EP3747852B1 (de) 2019-06-05 2022-10-26 Ustav organicke chemie a biochemie AV CR, v.v.i. Verbindungen zur chromatografischen trennung von seltenerdelementen und s-, p-, d- metallen, verfahren zur trennung und verwendung davon
WO2021013783A1 (en) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a12 as blood biomarker for the non-invasive diagnosis of endometriosis
WO2021013785A1 (en) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a9 as blood biomarker for the non-invasive diagnosis of endometriosis
EP4004551A1 (de) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG Substanz p als blutbiomarker zur nichtinvasiven diagnose von endometriose
EP4004553A1 (de) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a8 als blutbiomarker zur nichtinvasiven diagnose von endometriose
EP4004555A1 (de) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a6 als blutbiomarker zur nichtinvasiven diagnose von endometriose
JP7692892B2 (ja) 2019-08-09 2025-06-16 エフ. ホフマン-ラ ロシュ アーゲー 新規抗トロポニンt抗体
KR20220100883A (ko) 2019-11-15 2022-07-18 에프. 호프만-라 로슈 아게 환자 샘플의 질량분석법 측정을 위한 베타-락탐 항생제의 유도체화
KR102903735B1 (ko) 2020-10-30 2025-12-23 에프. 호프만-라 로슈 아게 담관암종의 표지자로서의 timp1
JP7851928B2 (ja) 2020-11-02 2026-04-27 エフ. ホフマン-ラ ロシュ アーゲー SARS-CoV-2ヌクレオカプシド抗体
WO2022207628A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf as blood biomarker for the non-invasive diagnosis of endometriosis
WO2022207685A1 (en) 2021-04-01 2022-10-06 F. Hoffmann-La Roche Ag Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis
CN117337394A (zh) 2021-05-17 2024-01-02 豪夫迈·罗氏有限公司 sFRP4作为血液生物标志物用于子宫腺肌病的非侵入性诊断
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体
WO2023131594A1 (en) 2022-01-05 2023-07-13 F. Hoffmann-La Roche Ag Derivatization of compounds in patient samples for therapeutic drug monitoring (tdm)
JP2025520600A (ja) 2022-06-23 2025-07-03 エフ. ホフマン-ラ ロシュ アーゲー 子宮内膜症を診断するためおよび子宮内膜症の病期を分類するための方法
EP4558826A1 (de) 2022-07-22 2025-05-28 F. Hoffmann-La Roche AG Fibroblastenwachstumsfaktor-bindendes protein 1 (fgfbp1) als (blut) biomarker zur diagnose des polyzystischen ovarialsyndroms
JP2025524027A (ja) 2022-07-22 2025-07-25 エフ. ホフマン-ラ ロシュ アーゲー 多嚢胞性卵巣症候群の診断のための(血液)バイオマーカーとしてのメテオリン様タンパク質(metrnl)
EP4558830A1 (de) 2022-07-22 2025-05-28 F. Hoffmann-La Roche AG Leukotrien-a4-hydrolase (lta4h) als (blut) biomarker zur diagnose des polyzystischen ovarialsyndroms
EP4565570A1 (de) * 2022-08-01 2025-06-11 Portland State University Kontraststoffe mit hoher relaxivität und stereoselektives präparat
CN121752901A (zh) 2023-07-28 2026-03-27 豪夫迈·罗氏有限公司 作为子宫内膜异位症的生物标志物的血清EphA1

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2609390A (en) * 1950-06-01 1952-09-02 Frederick C Bersworth Phosphonic alkylene polyamino acids and method of producing same
US3336221A (en) * 1964-11-05 1967-08-15 Calgon Corp Method of inhibiting precipitation and scale formation
US3331773A (en) * 1966-07-22 1967-07-18 Grace W R & Co Process for inhibiting precipitation in water
US3434969A (en) * 1967-08-11 1969-03-25 Calgon Corp Scale inhibiting
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
CA1341373C (en) * 1988-06-24 2002-07-02 Roberta C. Cheng Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5247077A (en) * 1989-06-23 1993-09-21 Celltech Limited Tri-aza macrocycles and processes for their preparation
GB8914543D0 (en) * 1989-06-23 1989-08-09 Parker David Chemical compounds
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
IL106159A0 (en) * 1992-06-30 1993-10-20 Dow Chemical Co Targeted delivery of growth factors for bone regeneration
EP0588229A3 (en) * 1992-09-12 1994-06-15 Hoechst Ag Macrocyclic chelating agents for the preparation of technetium or rhenium complexes

Also Published As

Publication number Publication date
DE69431660D1 (de) 2002-12-12
JPH08510245A (ja) 1996-10-29
DE69431660T2 (de) 2003-08-21
PL311643A1 (en) 1996-03-04
LV11430A (lv) 1996-08-20
CZ289595A3 (en) 1997-01-15
NO301829B1 (no) 1997-12-15
US5462725A (en) 1995-10-31
NO954440L (no) 1996-01-05
CA2162174A1 (en) 1994-11-24
HU9503174D0 (en) 1996-01-29
EP0711300A4 (de) 1996-03-12
AU6944794A (en) 1994-12-12
FI955319A0 (fi) 1995-11-06
LV11430B (en) 1997-04-20
SG46458A1 (en) 1998-02-20
FI955319L (fi) 1995-12-22
BG100192A (en) 1996-12-31
WO1994026275A1 (en) 1994-11-24
HUT74565A (en) 1997-01-28
NO954440D0 (no) 1995-11-06
CN1125905A (zh) 1996-07-03
FI955319A7 (fi) 1995-12-22
EP0711300A1 (de) 1996-05-15
EP0711300B1 (de) 2002-11-06
AU678583B2 (en) 1997-06-05

Similar Documents

Publication Publication Date Title
ATE227297T1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel
ATE316377T1 (de) Tricyclopolyazamacrocyclophosphonsäuren, ihre komplexe und derivate, für eine verwendung als kontrastmittel
ATE277058T1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
TR200103525T2 (tr) Bisiklik poliaminosit metal kompleksleri, bunları hazırlamak için yöntem ve bunların tıbbi görüntülemede kullanımı.
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
PL338339A1 (en) Novel derivatives of tetrazole
MY109602A (en) Heteroatoms-containing tricyclic compounds
ATE160943T1 (de) Bicycloazamakrocyclophosphon-säure, komplexe, konjugate, kontrastmittel und herstellung
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
DE60008400D1 (de) Triazolopyrimidinderivate
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
DE3673227D1 (de) 99mtc(iii)-agenzien zur myokardialen darstellung, in vivo nichtreduzierbar.
MY141501A (en) Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation
UA86379C2 (ru) Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties